Kindred Bio to Present at Craig-Hallum, Stifel, and Jefferies Conferences - WNEM TV 5

Kindred Bio to Present at Craig-Hallum, Stifel, and Jefferies Conferences

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Kindred Biosciences, Inc.

SAN FRANCISCO, May 21, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will participate in the 11th Annual Craig-Hallum Institutional Investor Conference in Minneapolis on May 28th.  Kindred Bio will present at the Stifel Dental and Veterinary Conference on May 28th and the Jefferies Global Healthcare Conference on June 2nd, both in New York City.  Details for the presentations are below:

Stifel Dental and Veterinary Conference:

Presentation date: Wednesday, May 28, 2014
Presenting time: 10:55 AM EDT
Presentation location: New York City

Jefferies Global Healthcare Conference:

Presentation date: Monday, June 2, 2014
Presenting time: 8:30 AM EDT
Presentation location: New York City

The Jefferies presentation will be webcast live over the Internet and can be accessed through the Investors/Events section of Kindred Bio's website at www.kindredbio.com. To access the live webcast, please log on to Kindred Bio's website approximately 15 minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for 90 days following the event.  

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company's lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.

Contact
Denise Bevers
Kindred Bio
denise.bevers@kindredbio.com
(650) 701-7909

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
WNEM
Powered by WorldNow CNN
All content © 2014, WNEM; Saginaw, MI. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.